Rett syndrome is a rare neurodevelopmental disorder resulting from de novo mutations in the X-linked Methyl-CpG Binding Protein 2 gene. Current treatments for Rett syndrome are solely symptomatic. Symptoms typically manifest between 6 to 18 months, marked by microcephaly and impaired motor coordination. The condition progresses until adulthood, entering a stable phase. Over 800 mutations are associated with Rett syndrome, the most common is the T158M located in the Methyl-Binding domain of MeCP2, significantly impacting its stability and function due to its role in DNA binding through recognising methylated CpG sites. MeCP2 is a nuclear protein forming condensates seen as speckles in NIH3T3 cells. A high-content phenotypic assay was developed to detect fluorescent MeCP2 speckles in NIH3T3 cells, enabling the identification of small molecules that stabilize MeCP2-T158M, rescuing speckle formation. Screening 3572 drugs revealed 18 hits that rescued at least 25% of speckles in the mutant cell line. Notably, histone deacetylase inhibitors emerged as one class of effective hits, showing 25% speckle rescue in mutant MeCP2 without toxicity, offering promise for novel drug discovery.